All Posts: mind
-
Georgetown’s Memory Disorders Program Marks 20th Year
(April 12, 2019) — When President Ronald Reagan announced in 1994 that he had Alzheimer’s disease, the man known as the “great communicator” tried his best to convey a sense of optimism. “I now begin the journey that will lead me into the sunset of my life. I know that for America there will always […]
Category: GUMC Stories
-
Training the Next Generation of Researchers in Movement Disorders
(February 8, 2019) — After she first developed a tremor in her right hand, years went by before Pam Cota was diagnosed with Parkinson’s disease by Fernando Pagan, MD (M’96, R’00), director of the MedStar Georgetown University Hospital Movement Disorders Clinic. The number of Parkinson’s disease patients expected to grow to 1.2 million by 2030, according […]
Category: GUMC Stories
-
Georgetown Physician Leads International Experts in Developing Treatment Guidelines for Huntington’s Disease Symptoms
(February 1, 2019) — A group of international experts in Huntington’s disease, led by Georgetown University Medical Center’s Karen Anderson, MD, has developed consensus guidelines for the clinical management of behavior symptoms caused by the incurable disease. Huntington’s disease is a fatal genetic disorder that impacts a person’s physical and mental abilities that is often accompanied […]
Category: GUMC Stories
-
Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases
Georgetown University today announces it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.
Category: News Release
-
Georgetown Clinical Trial Testing Nilotinib in Alzheimer’s Disease Begins
A clinical trial to examine the effect of nilotinib on clinical outcomes and biomarkers in people with mild to moderate Alzheimer’s disease has opened at Georgetown University Medical Center (GUMC).
Category: News Release
-
Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
TORONTO (July 27, 2016) — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, […]
Category: News Release
-
First-of-Its-Kind Study Explains Why Rest is Critical After A Concussion
Doctors who order several days of rest after a person suffers a concussion are giving sound advice, say researchers, and new data from animal models explains why. Georgetown University Medical Center neuroscientists say rest — for more than a day — is critical for allowing the brain to reset neural networks and repair any short-term injury. The new study in mice also shows that repeated mild concussions with only a day to recover between injuries leads to mounting damage and brain inflammation that remains evident a year after injury.
Category: News Release
-
Could Blood pressure drugs have a role in Alzheimer's Disease treatment?
WASHINGTON — In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer’s disease, say researchers at Georgetown University Medical Center (GUMC) and the National Institutes of Health.
Category: News Release
-
Researchers Report First Therapy Appearing to Reverse Decline in Parkinson’s
OCTOBER 17, 2015 – An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC). The drug, nilotinib (known as Tasigna® by Novartis) also led to statistically significant and encouraging changes in toxic […]
Category: GUMC Stories
-
Cancer Drug Improved Cognition and Motor Skills in Small Parkinson’s Clinical Trial
CHICAGO (Oct. 17, 2015) — An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small phase I clinical trial, report researchers at Georgetown University Medical Center (GUMC) in Washington. In addition, the drug, nilotinib (Tasigna® by Novartis), led to statistically significant […]
Category: News Release